Imagion Biosystems Secures Funding and Siemens Partnership

Imagion Biosystems Ltd. (AU:IBX) has released an update.

Imagion Biosystems, a company focused on early cancer detection, has secured the second tranche of a successful $3 million funding round, led by CPS Capital, to advance its MagSense® MRI imaging technology. The company has renewed its collaboration with Siemens to support an upcoming Phase 2 study, aiming to optimize imaging protocols and enhance cancer diagnosis. With a positive outlook for 2025, Imagion is gearing up to file an Investigational New Drug (IND) application with the FDA and initiate a Phase 2 study in the latter half of the year.

For further insights into AU:IBX stock, check out TipRanks’ Stock Analysis page.